The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low value, or the M1PAM and an acetylcholinesterase inhibitor.

The present disclosure relates to an acetylcholine receptor-binding peptide and, more particularly, to novel peptides which exhibit a wrinkle amelioration effect by binding the peptides to an acetylcholine receptor on which acetylcholine acts, thereby blocking secretion of acetylcholine. Peptides according to the present disclosure suppress secretion of acetylcholine by having a high binding strength with the acetylcholine receptor, thereby strongly binding the peptides to acetylcholine. Therefore, a cosmetic composition and a pharmaceutical composition comprising the peptides according to the present disclosure as an active ingredient exhibit an excellent wrinkle ameliorating effect.

Provided herein are methods for determining the level of muscarinic acetylcholine receptor subtype-(M1 receptor) anticholinergic activity in a blood serum sample, the method comprising the steps of removing protein from the blood serum sample by treatment with perchloric acid (PCA) to produce a PCA-treated serum sample; incubating the PCA-treated serum sample with a membrane preparation from cultured cells expressing the M1 receptor and an M1 receptor ligand; detecting an amount of binding of the M1 receptor ligand to the M1 receptor and comparing the amount of binding to a standard to determine the level of M1 receptor anticholinergic activity in the blood serum sample. Also provided are kits for performing the method.

This disclosure provides methods and compositions for treating diseases and disorders by targeting ILC2s that express the 7-nicotinic acetylcholine receptor (7nAChR).

Disclosed is a method for simultaneous analysis of neurotransmitters and/or their metabolites. The method includes (a) separating analytes including a plurality of neurotransmitters and/or their metabolites from a sample selected from body tissues, body fluids, secretions, and excretions, (b) derivatizing the analytes with ethyl chloroformate to obtain derivatives of the plurality of neurotransmitters and/or their metabolites, (c) separating the derivatives of the plurality of neurotransmitters and/or their metabolites by liquid chromatography, and (d) subjecting the separated derivatives of the neurotransmitters or their metabolites to multiple reaction monitoring (MRM) using a mass spectrometer. According to the method, a plurality of neurotransmitters in a very small amount of sample can be simultaneously analyzed in an accurate and rapid manner based on derivatization to increase the stability and ionization efficiency of the substances.

The present invention relates to methods for the detection of antibodies against members of the cardiac receptor family; kits for performing the methods of the invention; the use of the methods of the invention for the diagnosis, therapy and/or prophylaxis of one or more diseases, which are related to one or more members of the cardiac receptor family, and the use of the methods of the invention for a) the identification of modulators of the binding properties of antibodies against members of the cardiac receptor family orb) the identification of therapeutic agents for the treatment of one or more of the said diseases.

Acetylcholine and its receptors appeared in evolution before development of a nervous system. Cholinergic agonists functions include proliferation, differentiation, and cell-to-cell contact in protozoa] as well as vertebrate cells. Animal models for infection by Apicomplexan parasites require cell-to-cell contact followed by differentiation of parasite and host cells to produce clinical disease. Experimental infections are produced by introducing parasite infected leukocytes into a host. Binding cholinergic receptors on the parasites and leukocytes with levamisole HCl induces non-progressive infections and absence of signs of disease.

The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low value, or the M1PAM and an acetylcholinesterase inhibitor.

Disclosed herein are isolated recombinant cells for the expression of 64 nicotinic acetylcholine receptor (nAChR) and methods of use thereof.

Disclosed herein are isolated recombinant cells for the expression of 252 nicotinic acetylcholine receptor (nAChR) and methods of use thereof.